{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.97","upperLimit":"31.36","value":"16.7"},{"groupId":"OG001","lowerLimit":"18.67","upperLimit":"29.42","value":"23.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"257"}],"units":"Participants"}],"description":"For both A0 and A1, to evaluate the best overall response rate (stringent complete response \\[sCR\\]+ complete response \\[CR\\]+ very good partial response \\[VGPR\\]+ partial response \\[PR\\]) in patients with multiple myeloma who had previously received bortezomib and either thalidomide or lenalidomide, had relapsed after two or more therapies, and were refractory to the most recently received therapy","dispersionType":"95% Confidence Interval","groups":[{"description":"Subjects will receive carfilzomib 20 mg/m2 intravenously on Days 1, 2, 8, 9, 15, and 16 of a 28 day cycle\n\nResponse-evaluable Population: Enrolled patients who completed at least 1 cycle of carfilzomib and who underwent disease assessments at Screening, Cycle 1 Day 15, and Cycle 2 Day 24. This analysis set also included patients who discontinued treatment during this time due to an AE that was considered probably related to carfilzomib.","id":"OG000","title":"Carfilzomib (A0)"},{"description":"In Cycle 1, subjects will receive carfilzomib 20 mg/m2 intravenously on Days 1, 2, 8, 9, 15, and 16.If all doses are administered and well-tolerated over the 28-day cycle, beginning with Cycle 2 the dose will escalate to 27 mg/m2 intravenously on Days 1, 2, 8, 9, 15, and 16 for all subsequent cycles.\n\nResponse-Evaluable Population:\n\n1. had measurable disease at Baseline\n2. received at least 1 dose of carfilzomib\n3. underwent baseline disease response assessments and at least 1 post-baseline disease assessment, or discontinued protocol treatment before Cycle 2 Day 1 due to an AE that was considered to be possibly or probably related to carfilzomib","id":"OG001","title":"Carfilzomib (A1)"}],"paramType":"NUMBER","populationDescription":"Analysis population described in reporting groups below","reportingStatus":"POSTED","timeFrame":"A0: Subjects evaluated for disease response on Day 24 of Cycles 2, 4, 6, 9, and 12. Onset of response measured on Day 15 of Cycle 1. A1: Subjects evaluated for disease response on Day 15 of Cycle 1, Day 1 of Cycles 2 through 12 and at End of Study.","title":"Best Overall Response Rate (ORR)","type":"PRIMARY","unitOfMeasure":"% of participants w/ PR or better"}